Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Hindrik Mulder

Hindrik Mulder

Principal investigator

Hindrik Mulder

Glutamate dehydrogenase, insulin secretion and Type 2 Diabetes. A new means to protect the pancreatic β-cell?

Author

  • Isabel Göhring
  • Hindrik Mulder

Summary, in English

In this issue of Journal of Endocrinology, Dr Han and colleagues report a protective effect of the glutamate dehydrogenase-activator BCH under diabetes-like conditions that impair β-cell function in both a pancreatic β-cell line and in db/db mice. Based on these observations, the authors suggest that BCH could serve as novel treatment modality in Type 2 Diabetes. The present commentary discusses the importance of the findings. Some additional questions are raised, that may be addressed in future investigations, as is some concern regarding BCH treatment of β-cell failure.

Department/s

  • Diabetes - Molecular Metabolism
  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year

2012

Language

English

Pages

239-242

Publication/Series

Journal of Endocrinology

Volume

212

Issue

3

Document type

Journal article

Publisher

Society for Endocrinology

Topic

  • Endocrinology and Diabetes

Status

Published

Research group

  • Diabetes - Molecular Metabolism

ISBN/ISSN/Other

  • ISSN: 1479-6805